Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. 2010

Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands. hj.bontkes@vumc.nl

CD1d restricted, alpha-galactosylceramide (alphaGC) responsive invariant (i)NKT cells positively regulate immune responses. Both intravenous and intradermal administered alphaGC are known to activate iNKT cells. iNKT cells become unresponsive to a second intravenous alphaGC injection, whereas no data are available regarding potential anergy upon intradermal administration. Here, comparative analysis of two intradermal versus two intravenous injections in mice demonstrated that iNKT cell anergy was prevented by intradermal injection and when combined with a vaccine, superior tumor protection afforded by intradermally administered alphaGC. Moreover, human skin dendritic cells (DC) took up intradermally injected alphaGC and activated iNKT cells upon migration, while iNKT cells in human skin-draining lymph nodes expanded in response to alphaGC presented either by exogenously added DC or by CD1d positive antigen presenting cells in the lymph nodes. In conclusion, glycolipids such as alphaGC may greatly improve the efficacy of skin immunization strategies, targeting cutaneous and lymph node DC.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007271 Injections, Intradermal The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. Intradermal Injections,Injection, Intradermal,Intradermal Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell
D005260 Female Females
D005699 Galactosylceramides Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy. Galactocerebrosides,Galactosyl Ceramide,Galactosyl Ceramides,Galactosylceramide,Ceramide, Galactosyl,Ceramides, Galactosyl

Related Publications

Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
June 2009, Blood,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
December 2008, BMC immunology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
January 2018, Frontiers in immunology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
January 2018, Frontiers in immunology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
December 2020, European journal of preventive cardiology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
February 2000, Immunology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
June 2013, Journal of neuroimmunology,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
September 2009, Clinical immunology (Orlando, Fla.),
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
November 2009, ChemMedChem,
Hetty J Bontkes, and María Moreno, and Basav Hangalapura, and Jelle J Lindenberg, and Jan de Groot, and Sinéad Lougheed, and Hans J J van der Vliet, and Alfons J M van den Eertwegh, and Tanja D de Gruijl, and B Mary E von Blomberg, and Rik J Scheper
January 2021, PloS one,
Copied contents to your clipboard!